Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03439085 · OUTCOME

Median Progression Free Survival (PFS)

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers · Source last updated 2024-07-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 2 years

What was measured

Progression Free Surival is defined as time in months from start of study treatment to first documentation of objective tumor progression as assessed by RECIST v1.1; Will be summarized using the method of Kaplan and Meier and Cox proportional hazards models.

Groups in this outcome

Treatment Group

Patients received 7 mg of MEDI0457 intramuscularly (weeks 1, 3, 7, 12, and every 8 weeks thereafter) and durvalumab 1500 mg intravenously every 4 weeks starting at week 4.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment Group21

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment Group4.6Not reported2.87.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.8
        upper Limit
        7.2
        value
        4.6
denoms
  1. counts
    1. group Id
      OG000
      value
      21
    units
    Participants
description
Progression Free Surival is defined as time in months from start of study treatment to first documentation of objective tumor progression as assessed by RECIST v1.1; Will be summarized using the method of Kaplan and Meier and Cox proportional hazards models.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients received 7 mg of MEDI0457 intramuscularly (weeks 1, 3, 7, 12, and every 8 weeks thereafter) and durvalumab 1500 mg intravenously every 4 weeks starting at week 4.
    id
    OG000
    title
    Treatment Group
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 2 years
title
Median Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice